MedPath

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Phase 2
Completed
Conditions
Mesothelioma
Interventions
Registration Number
NCT00101283
Lead Sponsor
Eastern Cooperative Oncology Group
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether giving pemetrexed disodium with gemcitabine is more effective than giving pemetrexed disodium with carboplatin in treating malignant pleural mesothelioma.

PURPOSE: This randomized phase II trial is studying pemetrexed disodium with gemcitabine and pemetrexed disodium with carboplatin to see how well the combinations work compared to historical controls in treating patients with advanced malignant pleural mesothelioma.

Detailed Description

OBJECTIVES:

Primary

* Estimate the response rates in patients with advanced malignant mesothelioma of the pleura treated with pemetrexed disodium combined with either gemcitabine or carboplatin.

Secondary

* Assess the toxic effects of these regimens in these patients.

* Estimate survival time in patients treated with these regimens.

* Correlate smoking status with outcome in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. While randomized, the study is not a comparative study. Rather, outcomes on each arm will be compared to a historical control rate from previous studies. Randomization allows simultaneous testing of two experimental arms.

* Arm I: Patients receive intravenous (IV) pemetrexed disodium over 10 minutes and carboplatin IV over 30 minutes on day 1.

* Arm II: Patients receive pemetrexed disodium as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.

In both arms, treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Beginning approximately 5-10 days before the start of chemotherapy and continuing until approximately 3 weeks after completion of chemotherapy, all patients receive oral folic acid once daily and cyanocobalamin (vitamin B12) intramuscularly every 9 weeks.

Patients are followed every 3 months for 2 years and then every 6 months for 1 year.

PROJECTED ACCRUAL: A total of 32-60 patients (16-30 per treatment arm) will be accrued for this study within 12.8-27.0 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Histologically or cytologically confirmed advanced mesothelioma of the pleura

  • Measurable disease, as defined by RECIST criteria, within 4 weeks of randomization. Patients with pleural rinds not measurable by RECIST were eligible if disease was evaluable within 4 weeks of randomization using mesothelioma response criteria

  • May have undergone pleurodesis. If pleurodesis was performed, there must have been at least a 2-week delay before Pemetrexed administration. A CT must have been performed after 2 weeks after pleurodesis to serve as the baseline scan.

  • ECOG Performance Status of 0 or 1

  • Normal organ and marrow function, as defined by:

    • Absolute neutrophil count ≥ 1,500/ul
    • Platelet count ≥ 100,000/ul
    • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
    • AST and ALT ≤ 3 times ULN (5 times ULN if liver has tumor involvement)
    • Albumin ≥ 2.5 g/dL
    • Creatinine clearance ≥ 45 mL/min or Creatinine ≤ 2.0 g/dL
  • Age 18 years and over

  • Able to take folic acid and cyanocobalamin (vitamin B12)

  • Willing and able to take dexamethasone

  • Women of childbearing potential and sexually active men were required to use contraception during and for the first 3 months after the study

Exclusion Criteria

  • A candidate for curative surgery
  • Prior radiation therapy to the target lesion, unless the lesion was clearly progressing per RECIST criteria after prior radiation and the interval between the most recent radiation therapy and enrollment was at least 4 weeks
  • Prior systemic chemotherapy for mesothelioma. Prior intracavitary cytotoxic drugs or immunomodulators were not permitted, unless given for the purpose of pleurodesis.
  • Active infection or serious concomitant systemic disorder
  • Second primary malignancy, other than in situ malignancies or adequately treated basal cell carcinoma of the skin or other malignancy treated at least 3 years previously with no evidence of recurrence.
  • Treatment with an investigational agent within 4 weeks before enrollment
  • Known or suspected brain metastases
  • Women must not be pregnant or breastfeeding
  • Obviously malnourished or with a weight loss of greater than 10% in the preceding 6 weeks
  • Aspirin or other nonsteroidal anti-inflammatory drugs for 2 days before, during, and for 2 days after each administration of pemetrexed disodium (5 days before, during, and 2 days after each administration of pemetrexed disodium for piroxicam, naproxen, diflunisal, or nabumetone)
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pemetrexed/Gemcitabinegemcitabine hydrochloridePemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
Pemetrexed/Gemcitabinepemetrexed disodiumPemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
Pemetrexed/Carboplatinpemetrexed disodiumPemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to area under the curve (AUC) 5 IV over 30 minutes on day 1 of a 21-day cycle.
Pemetrexed/CarboplatincarboplatinPemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to area under the curve (AUC) 5 IV over 30 minutes on day 1 of a 21-day cycle.
Primary Outcome Measures
NameTimeMethod
Best Overall Response by RECIST Criteria (Version 1.0)Assessed every 2 cycles (6 weeks) while on treatment, then every 3 months for 2 years, then every 6 months for 1 year until disease progression

Number of eligible, treated participants in each response category by RECIST criteria. Response categories represent best response for each patient prior to progression.

Secondary Outcome Measures
NameTimeMethod
Progression-Free SurvivalAssessed every 3 months for 2 years, then every 6 months for 1 year

Time from randomization to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.

Overall SurvivalAssessed every 3 months for 2 years, then every 6 months for 1 year

Time from randomization to death. Patients alive at last follow-up were censored.

Trial Locations

Locations (115)

St. Rita's Medical Center

🇺🇸

Lima, Ohio, United States

Fox Chase Cancer Center - Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Mason District Hospital

🇺🇸

Havana, Illinois, United States

Case Comprehensive Cancer Center

🇺🇸

Cleveland, Ohio, United States

Indiana University Melvin and Bren Simon Cancer Center

🇺🇸

Indianapolis, Indiana, United States

Graham Hospital

🇺🇸

Canton, Illinois, United States

CCOP - Illinois Oncology Research Association

🇺🇸

Peoria, Illinois, United States

Oncology Hematology Associates of Central Illinois, PC - Peoria

🇺🇸

Peoria, Illinois, United States

Methodist Medical Center of Illinois

🇺🇸

Peoria, Illinois, United States

Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

🇺🇸

Minneapolis, Minnesota, United States

CCOP - Metro-Minnesota

🇺🇸

Saint Louis Park, Minnesota, United States

Bismarck Cancer Center

🇺🇸

Bismarck, North Dakota, United States

Fairview Ridges Hospital

🇺🇸

Burnsville, Minnesota, United States

Meeker County Memorial Hospital

🇺🇸

Litchfield, Minnesota, United States

Regions Hospital Cancer Care Center

🇺🇸

Saint Paul, Minnesota, United States

HealthEast Cancer Care at St. Joseph's Hospital

🇺🇸

Saint Paul, Minnesota, United States

Ridgeview Medical Center

🇺🇸

Waconia, Minnesota, United States

Hennepin County Medical Center - Minneapolis

🇺🇸

Minneapolis, Minnesota, United States

Miller - Dwan Medical Center

🇺🇸

Duluth, Minnesota, United States

Mercy and Unity Cancer Center at Unity Hospital

🇺🇸

Fridley, Minnesota, United States

St. Francis Cancer Center at St. Francis Medical Center

🇺🇸

Shakopee, Minnesota, United States

Minnesota Oncology Hematology, PA - Maplewood

🇺🇸

Maplewood, Minnesota, United States

CCOP - Duluth

🇺🇸

Duluth, Minnesota, United States

Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center

🇺🇸

Robbinsdale, Minnesota, United States

Park Nicollet Cancer Center

🇺🇸

Saint Louis Park, Minnesota, United States

Fairview Southdale Hospital

🇺🇸

Edina, Minnesota, United States

HealthEast Cancer Care at St. John's Hospital

🇺🇸

Maplewood, Minnesota, United States

United Hospital

🇺🇸

Saint Paul, Minnesota, United States

Mercy and Unity Cancer Center at Mercy Hospital

🇺🇸

Coon Rapids, Minnesota, United States

HealthEast Cancer Care at Woodwinds Health Campus

🇺🇸

Woodbury, Minnesota, United States

Minnesota Oncology Hematology, PA - Woodbury

🇺🇸

Woodbury, Minnesota, United States

Mid Dakota Clinic, PC

🇺🇸

Bismarck, North Dakota, United States

St. Alexius Medical Center Cancer Center

🇺🇸

Bismarck, North Dakota, United States

Fox Chase Virtua Health Cancer Program at Virtua West Jersey

🇺🇸

Voorhees, New Jersey, United States

CCOP - Christiana Care Health Services

🇺🇸

Newark, Delaware, United States

Mayo Clinic - Jacksonville

🇺🇸

Jacksonville, Florida, United States

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

🇺🇸

New Brunswick, New Jersey, United States

Sparrow Regional Cancer Center

🇺🇸

Lansing, Michigan, United States

Cancer Institute of New Jersey at Cooper - Voorhees

🇺🇸

Voorhees, New Jersey, United States

Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center

🇺🇸

La Crosse, Wisconsin, United States

Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton

🇺🇸

Marlton, New Jersey, United States

Tunnell Cancer Center at Beebe Medical Center

🇺🇸

Lewes, Delaware, United States

Union Hospital Cancer Program at Union Hospital

🇺🇸

Elkton, Maryland, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

🇺🇸

Baltimore, Maryland, United States

Eastern Connecticut Hematology and Oncology Associates

🇺🇸

Norwich, Connecticut, United States

Borgess Medical Center

🇺🇸

Kalamazoo, Michigan, United States

Genesys Hurley Cancer Institute

🇺🇸

Flint, Michigan, United States

Hurley Medical Center

🇺🇸

Flint, Michigan, United States

St. John Macomb Hospital

🇺🇸

Warren, Michigan, United States

Sanford Cancer Center at Sanford USD Medical Center

🇺🇸

Sioux Falls, South Dakota, United States

CCOP - Northern New Jersey

🇺🇸

Hackensack, New Jersey, United States

Veterans Affairs Medical Center - East Orange

🇺🇸

East Orange, New Jersey, United States

Hopedale Medical Complex

🇺🇸

Hopedale, Illinois, United States

Mayo Clinic Cancer Center

🇺🇸

Rochester, Minnesota, United States

Saint Joseph Mercy Cancer Center

🇺🇸

Ann Arbor, Michigan, United States

CCOP - Michigan Cancer Research Consortium

🇺🇸

Ann Arbor, Michigan, United States

Medcenter One Hospital Cancer Care Center

🇺🇸

Bismarck, North Dakota, United States

Rush-Copley Cancer Care Center

🇺🇸

Aurora, Illinois, United States

St. Joseph Medical Center

🇺🇸

Bloomington, Illinois, United States

Winship Cancer Institute of Emory University

🇺🇸

Atlanta, Georgia, United States

Memorial Hospital

🇺🇸

Carthage, Illinois, United States

Galesburg Cottage Hospital

🇺🇸

Galesburg, Illinois, United States

Decatur Memorial Hospital Cancer Care Institute

🇺🇸

Decatur, Illinois, United States

Joliet Oncology-Hematology Associates, Limited - West

🇺🇸

Joliet, Illinois, United States

Kewanee Hospital

🇺🇸

Kewanee, Illinois, United States

BroMenn Regional Medical Center

🇺🇸

Normal, Illinois, United States

Trinity Cancer Center at Trinity Medical Center - 7th Street Campus

🇺🇸

Moline, Illinois, United States

Community Cancer Center

🇺🇸

Normal, Illinois, United States

Community Hospital of Ottawa

🇺🇸

Ottawa, Illinois, United States

Cancer Treatment Center at Pekin Hospital

🇺🇸

Pekin, Illinois, United States

Proctor Hospital

🇺🇸

Peoria, Illinois, United States

Oncology Hematology Associates of Central Illinois, PC - Ottawa

🇺🇸

Ottawa, Illinois, United States

OSF St. Francis Medical Center

🇺🇸

Peoria, Illinois, United States

Illinois Valley Community Hospital

🇺🇸

Peru, Illinois, United States

Perry Memorial Hospital

🇺🇸

Princeton, Illinois, United States

St. Margaret's Hospital

🇺🇸

Spring Valley, Illinois, United States

Elkhart General Hospital

🇺🇸

Elkhart, Indiana, United States

Veterans Affairs Medical Center - Indianapolis

🇺🇸

Indianapolis, Indiana, United States

Regional Cancer Center at Memorial Medical Center

🇺🇸

Springfield, Illinois, United States

William N. Wishard Memorial Hospital

🇺🇸

Indianapolis, Indiana, United States

Howard Community Hospital

🇺🇸

Kokomo, Indiana, United States

Center for Cancer Therapy at LaPorte Hospital and Health Services

🇺🇸

La Porte, Indiana, United States

Saint Anthony Memorial Health Centers

🇺🇸

Michigan City, Indiana, United States

Memorial Hospital of South Bend

🇺🇸

South Bend, Indiana, United States

CCOP - Northern Indiana CR Consortium

🇺🇸

South Bend, Indiana, United States

McFarland Clinic, PC

🇺🇸

Ames, Iowa, United States

Saint Joseph Regional Medical Center

🇺🇸

South Bend, Indiana, United States

Cedar Rapids Oncology Associates

🇺🇸

Cedar Rapids, Iowa, United States

Siouxland Hematology-Oncology Associates, LLP

🇺🇸

Sioux City, Iowa, United States

St. Luke's Regional Medical Center

🇺🇸

Sioux City, Iowa, United States

Oakwood Cancer Center at Oakwood Hospital and Medical Center

🇺🇸

Dearborn, Michigan, United States

Foote Memorial Hospital

🇺🇸

Jackson, Michigan, United States

West Michigan Cancer Center

🇺🇸

Kalamazoo, Michigan, United States

Bronson Methodist Hospital

🇺🇸

Kalamazoo, Michigan, United States

Lakeland Regional Cancer Care Center - St. Joseph

🇺🇸

Saint Joseph, Michigan, United States

Seton Cancer Institute at Saint Mary's - Saginaw

🇺🇸

Saginaw, Michigan, United States

Hutchinson Area Health Care

🇺🇸

Hutchinson, Minnesota, United States

Aultman Cancer Center at Aultman Hospital

🇺🇸

Canton, Ohio, United States

Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest

🇺🇸

Allentown, Pennsylvania, United States

Penn State Cancer Institute at Milton S. Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Lewistown Hospital

🇺🇸

Lewistown, Pennsylvania, United States

Albert Einstein Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Avera Cancer Institute

🇺🇸

Sioux Falls, South Dakota, United States

Mount Nittany Medical Center

🇺🇸

State College, Pennsylvania, United States

Eureka Community Hospital

🇺🇸

Eureka, Illinois, United States

Galesburg Clinic, PC

🇺🇸

Galesburg, Illinois, United States

McDonough District Hospital

🇺🇸

Macomb, Illinois, United States

CCOP - Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

Carle Cancer Center at Carle Foundation Hospital

🇺🇸

Urbana, Illinois, United States

Mercy Medical Center - Sioux City

🇺🇸

Sioux City, Iowa, United States

Duluth Clinic Cancer Center - Duluth

🇺🇸

Duluth, Minnesota, United States

Summa Center for Cancer Care at Akron City Hospital

🇺🇸

Akron, Ohio, United States

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center

🇺🇸

Madison, Wisconsin, United States

Medical X-Ray Center, PC

🇺🇸

Sioux Falls, South Dakota, United States

Van Elslander Cancer Center at St. John Hospital and Medical Center

🇺🇸

Grosse Pointe Woods, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath